Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BACTERIAL VAGINOSIS Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

NCT06469164
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
BNT331, Placebo
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

NCT06665126
View directory record Official record
Conditions
Bacterial Vaginosis, Yeast Infection
Interventions
Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
Dietary Supplement
Lead sponsor
Happy V
Industry
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

NCT02432404
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
NuvaRing
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Early Phase 1 Interventional

Vaginal lIve Biotherapeutic RANdomized Trial

NCT06135974
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LC106, LC115, Placebo, Metronidazole Oral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Metronidazole Gel 1.3%

NCT02392026
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Metronidazole Gel
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Long Beach, California • Paramount, California • Bardstown, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validity of Patient-Collected Wet Mounts

NCT02641717
View directory record Official record
Conditions
Vaginal Discharge, Trichomonas, Candidiasis, Vaginosis, Bacterial, Vaginitis
Interventions
vaginal swab
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 26, 2026, 12:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis

NCT02203942
View directory record Official record
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis, Trichomoniasis
Interventions
NAAT testing
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 26, 2026, 12:59 PM EDT
Withdrawn Not applicable Interventional

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

NCT00682721
View directory record Official record
Conditions
Bacterial Vaginosis, Herpes Simplex Virus Type II
Interventions
Placebo, Valacyclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of DARE-BV1

NCT05354050
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
DARE-BV1
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 26, 2026, 12:59 PM EDT
Completed No phase listed Observational

Clinical Trial to Survey Results of Flourish Vaginal Care System for Recurrent Bacterial Vaginosis

NCT03734523
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Flora Imbalance
Interventions
Flourish Vaginal Care System
Combination Product
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Concord, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 26, 2026, 12:59 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method

NCT02558179
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
American International Biotechnology
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
View directory record Official record
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

NCT01055106
View directory record Official record
Conditions
Vaginosis, Bacterial, Vaginal Infection
Interventions
GW05, Metronidazole
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
20
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

NCT00635622
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LACTIN-V, Placebo control substance
Drug
Lead sponsor
Osel, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Sep 26, 2026, 12:59 PM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 26, 2026, 12:59 PM EDT
Terminated Phase 1Phase 2 Interventional

GoldenCareTM for the Treatment of Bacterial Vaginosis

NCT01762670
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GoldenCare, Metronidazole
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

NCT02709005
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
5% Monolaurin Vaginal Gel, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Bacterial Vaginosis Home Screening to Prevent STDs

NCT00667368
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 25 Years · Female only
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina

NCT00194324
View directory record Official record
Conditions
Health, Vulvovaginal Candidiasis
Interventions
Miconazole nitrate, Magnetic resonance imaging, Moderate levels of exercise
Drug · Procedure · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

NCT02209519
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Metronidazole (male partner), Placeob (male partner)
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pell City, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 26, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

NCT04370548
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
DARE-BV1clindamycin phosphate vaginal gel, 2%
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 26, 2026, 12:59 PM EDT